DeepSight Technology Raises $25 Million for Medical Imaging Platform

Cleerly, an AI-powered medical imaging company creating a new standard of care for coronary artery disease, raised $43 million in Series B funding.

Vensana Capital led the financing with participation from LRVHealth, New Leaf Venture Partners, DigiTx Partners, the American College of Cardiology, Cigna Ventures, and existing investors. With the current round, the company has raised $54 million in total funding.

With this funding, Cleerly plans to scale its commercial reach, expand operational capabilities and strategic partnerships, and continue to grow its focus on industry-leading research and development.

According to the company, its digital care pathway leverages non-invasive coronary computed tomography (CT) angiography to perform comprehensive coronary artery phenotyping through AI-enabled and FDA-cleared solutions.

James K. Min, MD FACC, and founder and CEO of Cleerly, commented: “Advanced imaging has been key to diagnosing and preventing the most common causes of cancer for years, but we’re not using it yet to prevent the most common cause of death. We use 3D mammograms, colonoscopies, and lung CT scans to find and prevent breast, colon, and lung cancer, but we haven’t had similar capabilities for the world’s number one killer – heart disease. Through the application of artificial intelligence that is constantly being refined with our unprecedented volume of accruing and exclusive clinical data, Cleerly is finally bringing heart disease diagnosis and prevention into the twenty-first century”.

“We see Cleerly as the future of how coronary artery disease will be evaluated, and we support the company’s mission to tailor a personalized approach to diagnosis, management, and treatment, and to validate all of this with world-class clinical evidence of utility and cost-effectiveness. With Cleerly’s industry-leading technology platform and inherent value propositions, we believe Cleerly is ideally positioned to inform a new standard of care for how we manage coronary artery disease at scale”, said Justin Klein, MD, JD, Managing Partner at Vensana Capital.

Digital health companies raised $7.2 billion in Q1 2021, according to Mercom’s Q1 2021 Digital Health Funding and M&A Report.